Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients
作者： Sandrine Hayette , Kaddour Chabane , Mauricette Michallet , Estelle Michallat , Pascale Cony-Makhoul
DOI: 10.1016/J.LEUKRES.2010.06.030
关键词:
摘要: This report aims to more accurately define the frequency of involvement SRC Family Kinases (SFKs) in imatinib- and dasatinib-resistant CML patients. Clinical samples were analysed during vivo treatment. We confirmed high SFKs Tyrosine kinase inhibitor-resistant (52% cases) even further progressive disease blast crises (60% cases). The deregulation is also observed patients harboring BCR-ABL mutations. In T315I F317L mutated patients, CML-resistance appears be promoted by protein reactivation once clone has decreased on Omacetaxine.
archives-ouvertes.fr
elsevier.com
sci-hub.se 参考文章(31)
Patrizia Scapini, Shalini Pereira, Hong Zhang, Clifford A. Lowell, Multiple roles of Lyn kinase in myeloid cell signaling and function Immunological Reviews. ,vol. 228, pp. 23- 40 ,(2009) , 10.1111/J.1600-065X.2008.00758.X
Timothy Hughes, Michael Deininger, Andreas Hochhaus, Susan Branford, Jerald Radich, Jaspal Kaeda, Michele Baccarani, Jorge Cortes, Nicholas CP Cross, Brian J Druker, Jean Gabert, David Grimwade, Rüdiger Hehlmann, Suzanne Kamel-Reid, Jeffrey H Lipton, Janina Longtine, Giovanni Martinelli, Giuseppe Saglio, Simona Soverini, Wendy Stock, John M Goldman, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood. ,vol. 108, pp. 28- 37 ,(2006) , 10.1182/BLOOD-2006-01-0092
Rong Chen, Varsha Gandhi, William Plunkett, A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Research. ,vol. 66, pp. 10959- 10966 ,(2006) , 10.1158/0008-5472.CAN-06-1216
V Roginskaya, S Zuo, E Caudell, G Nambudiri, AJ Kraker, SJ Corey, Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia. ,vol. 13, pp. 855- 861 ,(1999) , 10.1038/SJ.LEU.2401429
Frederic Luciano, Jean-Ehrland Ricci, Patrick Auberger, Cleavage of Fyn and Lyn in their N-terminal unique regions during induction of apoptosis: a new mechanism for Src kinase regulation Oncogene. ,vol. 20, pp. 4935- 4941 ,(2001) , 10.1038/SJ.ONC.1204661
Susanne Danhauser-Riedl, Bertold Emmerich, Michael Hallek, Brian J. Druker, Markus Warmuth, Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Research. ,vol. 56, pp. 3589- 3596 ,(1996)
Su Chu, Helen Xu, Neil P. Shah, David S. Snyder, Stephen J. Forman, Charles L. Sawyers, Ravi Bhatia, Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment Blood. ,vol. 105, pp. 2093- 2098 ,(2005) , 10.1182/BLOOD-2004-03-1114
Nicholas J. Donato, Ji Yuan Wu, Jonathan Stapley, Gary Gallick, Hui Lin, Ralph Arlinghaus, Moshe Talpaz, BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. ,vol. 101, pp. 690- 698 ,(2003) , 10.1182/BLOOD.V101.2.690
Ji Wu, Feng Meng, Henry Lu, Ling Kong, William Bornmann, Zhenghong Peng, Moshe Talpaz, Nicholas J. Donato, Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells Blood. ,vol. 111, pp. 3821- 3829 ,(2008) , 10.1182/BLOOD-2007-08-109330
R Villuendas, J L Steegmann, M Pollán, L Tracey, A Granda, E Fernández-Ruiz, L F Casado, J Martínez, P Martínez, L Lombardía, L Villalón, J Odriozola, M A Piris, Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia. ,vol. 20, pp. 1047- 1054 ,(2006) , 10.1038/SJ.LEU.2404197